The Second Annual Targeting the Microbiome – Part II (September 21 - 22, 2016, Boston, MA), highlights growing importance of the microbiome for development of new diagnostics, therapies and cures, with Keynote presentation by Amrita Therapeutics Senior Science Mentor Ananda Chakrabarty, and participation of CEO Susan K. Finston as both a speaker and Chairperson for September 22nd (Day 2).
Amrita Therapeutics CEO Susan K. Finston is a panelist at the Festival of Genomics Boston (June 27-29, 2016, Boston Convention Center), discussing the challenges and opportunities of commercializing microbiomic therapies like Amrita's oncology peptide AT-01C. More information on the microbiome discussion panel is available here.
The Microbiome Drug Developent Summit 2016 (June 29-30, 2016, Boston), features a case study presented by Amrita Therapeutics CEO Susan K. Finston, on the SMAR1 'master regulator' and role of biomarker validation in commercialization of microbiome technologies. Download the SMAR1 Case Study Slides here.
BioCentury focuses on the growing importance of the microbiome for innovative drug development in its May 9, 2016 Cover Story: Community Organizers; How studying bacteria by function is reshaping microbiome therapies, and features Amrita Therapetics in the accompanying Table: Traditional drugs from bugs. (paywall).
The Second Annual Arrowhead Translational Microbiome Conference (April 20 - 21, 2016, Boston, MA), includes Amrita Therapeutics Science Mentor and Co-Founder Ananda Chakrabarty as Featured Speaker, followed by a panel chaired by Amrita Therapeutics CEO Susan K. Finston on intellectual property (IP) considerations relating to patentability of microbiomic technologies.
Amrita Therapeutics is pleased to announce the Company's submission to the FDA of a pre-IND meeting request to discuss clinical development plans for lead oncology peptide AT-01C on March 16, 2016. More details available here.
Amrita Therapeutics filed our complete specification for our latest utility patent application for modified bacterial peptides from the microbiome as an anti-cancer agent on March 7, 2016.
Amrita Therapeutics congratulates Technical Science Advisor, Dr. Samit Chattopahdyay, on his induction as Fellow, The World Academy of Sciences (TWAS) (New Delhi).
Nature Microbiology reports that US federally funded microbiome research over three fiscal years (FY12-14) has grown to an estimated US$920 million, with approximately two-thirds focusing on studies of human-asociated microbiomes and animal-model based studies. More details available here.
Amrita Therapeutics has been awarded its first patent protecting bacterial oncology peptides including claims for treatment of breast, ovarian, cervical, pancreatic, colon, prostate and liver cancers, granted by the Japan Patent Office for Application Number 2013-530856. More details are available here.
Amrita Therapeutics and ECRC LLC are pleased to announce collaboration on regulatory support and drug development strategy for AT-01C, a p53 (tumor suppressor activator) and the related SMAR1 in vitro diagnostic test to identify patients most likely to benefit from AT-01C therapy. The ECRC Press Release is available here.
Amrita Therapeutics welcomes Lin Sun-Hoffman, Ph.D., J.D., with past experience including as Patent Counsel for Life Technologies/Applied Biosystems, Inc., Celera Genomics, and Patent Examiner at the US PTO, as US Intellectual Property (IP) Counsel.
Life Sciences Foundation's Fall 2015 magazine focuses on the Microbiome, including a wonderful profile of Amrita Therapeutics Science Mentor and co-founder, biotechnology pioneer Ananda M. Chakrabarty, available here.
Amrita Therapeutics congratulates Technical Science Advisor Samit Chattopahdyay, PhD., on his recent appointment as Director of the CSIR – Indian Insitute of Chemical Biology (IICB), located in Kolkata India and counted among India's premiere scientific research institutes. More details on IICB are available here.
Amrita Therapeutics' completion of Pre-Clinical Milestone triggers release of additional funds from GVFL, the pioneer of venture finance in India: "We are pleased with the recent progress we have made to complete mechanism of action (MOA) studies and initiate in vivo research, and appreciate the continued confidence and ongoing financial support of GVFL," said Susan K. Finston, CEO and Managing Director. More details available here.
Technical Science Advisor Dr. Samit Chattopadhyay's pathbreaking research on the important role of scaffold/matrix associated region-binding protein (SMAR1) in tumor suppression is highlighted by leading India media including The Indian Express, available here.
Amrita Therapeutics CEO Susan K. Finston is participating in the TTS North America Summit at the University of Illinois at Chicago (UIC), July 20 - 21, 2015. The TTS Global Initiative brings together KOLs and decision makers from key stakeholders in biotech innovation for candid discussion, networking, and business development. More details available here.
Amrita Therapeutics Technical Science Advisor Dr. Samit Chattopadhyay's latest article in the Proceedings of the National Academy of Sciences (PNAS): “Nuclear matrix-associated protein SMAR1 regulates alternative splicing via HDA6-mediated deacetylation of Sam68,” discusses the important role of scaffold/matrix associated region-binding protein (SMAR1) in tumorigenesis and metastatic proclivity of cancer cells, available here.
Amrita Therapeutics congratulates our technology commercialization partner CSIR-Tech Private Limited (CTPL) on establishment of the Indian Science Venture Fund (ISVF). This important milestone and other achievements from CTPL's first three years of are highlighted in the latest IIM Ahmedabad Case Study, available here.
Amrita Therapeutics files a new provisional patent for derived, truncated peptides with anti-cancer activity with tumor suppressor (p53) and anti-metastasis mechanisms of action (MOA) on March 5, 2015.
Amrita Therapeutics is pleased to announce engagement of CSIR-Tech Private Limited to search for a Strategic Partner for commercialization of Amrita's novel Oncology Therapies. Full details available here.
Amrita Therapeutics Co-Founder and Senior Science Mentor Ananda Chakrabarty reviews: A History of New Ideas in the Biosciences, JBioscience (January 2015) 65 (1): 102– 104. The book review is available here.
Amrita Therapeutics Founder and Senior Science Mentor, Ananda Chakrabarty, participated as a featured speaker in the closing session of 'Bio-Invest in Gujarat: Reshaping Human Lives through Biotechnology, held in the run up to the Vibrant Gujarat 2015 Global Summit, Ghandinagar, December 6, 201. More information is available here.
Amrita Therapeutics CEO / Managing Director Susan K. Finston participated in "Enhancing the Innovative Capacity of MSMEs," Half-Day Seminar, organized jointly by the Wadhwani Foundation and CSIR NISTADS, New Delhi, September 16, 2014. More information is available here.
Amrita Therapeutics Technical Advisor Samit Chattopadhyay, PhD., presented latest data on the Company's ongoing research activities at a closed science briefing for Amrita Therapeutics investors and R&D Collaborators, highlighting SMAR1,its important role in cancer to activate p53 (guardian of the genome), and the effectiveness of AT-01C, AT-01D to shrink tumors and prevent metastasis of cancer cells, Ahmedabad, September 14, 2014.
For more information about Amrita Therapeutics peptide cancer therapies, please contact info@AmritaTherapeutics.com
Attending Bio One-on-One Partnering at BIO 2014 in San Diego? To learn more about partnering opportunities with Amrita Therapeutics, contact Roger Hill / Cathy Miner at Willow Tree Capital Group. #bio2014 #BIO1x1
Amrita Therapeutics' first utility and PCT patent application relating to novel peptides for use as anti-cancer therapies is published by the USPTO and EPO, available here.
Amrita Therapeutics' first utility and PCT patent application relating to novel peptides for use as anti-cancer therapies is published by the USPTO and EPO, available here.
Amrita Therapeutics' Board of Directors welcomes Dr. Samit Chattopahdyay, a member of the Indian Department of Biotechnology (DBT) task force on cancer research and a recipient of the J.S. Bose National Fellow for his work on gene regulation, as Technical Science Advisor to the Company.
Amrita Therapeutics CEO Susan K Finston participates in the Wadhwani Foundation half-day seminar on: "Promoting Innovation in MDMEs through Public-Private Partnership Programmes," held in New Delhi, February 19, 2014.
Bugging Cancer – Daring to Dream, an exciting fictional account based on real scientific progress, written by Amrita Therapeutics Co-Founder Ananda Chakrabarty and the Chicago OncoGroup and published by Logos Press, is available now at Amazon.
Amrita Therapeutics CEO Susan K Finston blogs about emerging "Guardian of the Genome" p53 therapies like Amrita Therapeutics' AT-01 and derivative peptides pre- clinical candidate drugs, available here.
Amrita Therapeutics initiates R&D collaboration for Mechanism of Action (MOA studies) for AT-01 and derivative peptidees with Dr. Samit Chattopahdyay, a member of the Indian Department of Biotechnology (DBT) task force on cancer research and a recipient of the J.S. Bose National Fellow for his work on gene regulation, at the National Center for Cell Science (NCCS) in Pune, India.
Amrita Therapeutics Co-Founder and Senior Science Advisor Ananda M. Chakrabarty, PhD., addresses the Amercan Intellectual Property Law Association (AIPLA) Biotechnology Committee at the AIPLA Annual Meeting, October 25, 2013, Washington DC, highlighting upcoming publication of the fictionali work: Bugging Cancer. For more information on the AIPLA program is available here.
Amrita Therapeutics completes PCT national phase applications for effective protection of novel peptide therapies and related protein for the treatment of cancers and HIV/AIDS.
Amrita Therapeutics CEO Susan K Finston discusses the challenges facing early stage biotech discovery companies and related crowdfunding at 700ForScience.com
Mayank Chhaya's Interview of Amrita Therapeutics CEO Susan K Finston on the Amrita Breast Cancer Device (ABCD).
Amrita Therapeutics launches its second social media campaign: The Amrita Breast Cancer Device IndieGoGo Campaign to increase awareness of the revolutionary combination medical device for safer, localized therapy for breast cancer patients.
Amrita Therapeutics at BIO 2013: CEO Susan K. Finston provides an update on Amrita's commercialization of innovative cancer therapies and the Amrita Breast Cancer Device (ABCD) in the Role of Public-Private Partnerships in Addressing Non-Communicable Diseases in Low and Middle-Income Countries, Wednesday, April 24, 2013. Senior Science Mentor and Co-Founder Ananda M. Chakrabarty tells the story of the invention of the Amrita Breast Cancer Device as part of the India Half-Day Program, Monday, April 22, 2013.
Amrita Therapeutics CEO Susan K. Finston explores the importance of innovative drug development for development at the upcoming Global Access to Medicines Conference on April 12, 2013 at Sheldon Hall, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, April, 2:00 pm – 6:00 pm. This event will provide thoughtful consideration of ongoing challenges relating to access to medicines, will formally launch a new Access to Medicines Network at Hopkins. To register for the event, click here.
Following release of Draft Guidelines, a period for public comment and dialogue with stakeholders including Amrita Therapeutics Ltd., the Indian Patent Office (IPO) has issued final Guidelines for Examination of Biotechnology Applications for Patent, available here.
Amrita Therapeutics Co-Founder and Senior Science Advisor Ananda M. Chakrabarty, PhD., submits an amicus brief to the U.S. Supreme Court supporting the proposition that isolated portions of genes should be considered patentable in cases where "a specific, substantial, and credible utility" can be demonstrated that is also substantially different from what exists in nature. The brief may be downloaded here.
Amrita Therapeutics CEO Susan Finston blogs at biotechblog.com about the intersection of the patent exhaustion doctine and effective protection for reinvented (digital) articles following the U.S. Surpreme Court oral argument in Bowman v. Monsanto.
Amrita Therapeutics submits comments on the Indian Patent Office (IPO) Draft Guidelines for Examination of Patent Applications, available here. Additional comments received by the IPO are available online here.
Interview with Amrita Therapeutics Senior Science Mentor Ananda M. Chakrabarty, PhD., on the importance of providinga better balance between incentives for innovation and commercialization of life-saving technologies and ensuring affordability of existing therapies, available here.
Amrita Therapeutics Senior Science Mentor Ananda M. Chakrabarty, PhD., provides insights into possible therapies to prevent occurence or re-occurrence of cancers for high-risk patient populations, available here.
Amrita Therapeutics' innovative research platform and oncology research is highlighted by Asia's leading biotechnology magazine: BioSpectrum; The Business of Science: "Amrita develops cancer therapies made in India," published on October 29, 2012, available here.
Amrita Therapeutics CEO Susan K. Finston is attending the 3rd Annual Tech Transfer Summit North America, the world's leading international technology transfer, collaboration, partnering and licencing platform for key stakeholders in the Biotech sector, October 22 - 23, 2012, at Johns Hopkins Univeristy, Montgomery County, MD.
Amrita Therapeutics Senior Science Mentor Ananda M. Chakrabarty, PhD., provides insights into exciting research on preventative therapies for individuals at highest risk for cancer due to BRCA1, BRCA2 gene mutations in remarks at the Pauline Newman and Giles S. Rich American Inns of Court Joint Program, October 10, 2012, at the Court of Appeals for the Federal Circuit, October 10, 2012.
A portion of his remarks may be viewed below:
Amrita Therapeutics Senior Science Mentor Ananda M. Chakrabarty, PhD., leads off the Fall 2012 Action Speaks panel discussion series, "Private Rights and Public Fights," in Providence, Rhode Island, on October 3, 2012. More coverage of the event is available here.
Amrita Therapeutics CEO and Managing Director, Susan K. Finston, explores the increasingly critical role of Data Exclusivity (DE) for innovative industry as a speaker at the OMICS International Conference and Exhibition on Biowaivers & Biosimilars, San Antonio, TX (September 10 - 12, 2012), presenting "Understanding Data Exclusivity: The Biologics Price Competition and Innovation Act of 2009 (BPCI Act)."
Amrita Therapeutics signs R&D Agreement, transfers early research lab to University of Delhi South Campus (UDSC) Technology Based Incubator (TBI), centrally located in New Delhi, India.
Amrita Therapeutics Co-founder Ananda Chakrabarty is a plenary spearker at the International Symposium on Molecular Medicine and Biotechnology in Ljubljana, presenting: "Eradicating cancer in our lifetime: taking the first steps," at the Univeristy of Ljubljana, Slovenia (27 – 29 June 2012).
Amrita Therapeutics presents an International Case Study, "Cross-Cultural Drug Development: Leveraging European R&D and Tech Transfer Strengths with Emerging Market Bio-Discovery for Innovative, Affordable Therapies and Devices,"Thursday, June 21, 2012, at the2012 BIO International Convention. Details on speakers and topics are available here. The event was blogged here; the panel introduction / scenesetter is below:
Amrita Therapeutics is featured in Pharma Express Review of India's innovative Small and Medium Size (SME) biotechnology companies (June 19, 2012), available here.
Amrita Therapeutic filed a provisional patent application for Methods of Isolation of Promiscuous Protein Drugs from Microorganisms (May 2012) (Peptide Antibiotics).
Amrita's Susan Finston participates in a panel presentation as part of American University's Washington College of Law 2012 Founders Celebration: "Traditional Knowledge and Cultural Expression: Whose Property Is It Anyway?", Washington, DC, April 11, 2012, 6:30 – 7:45 pm. More details available here.
Amrita Therapeutic filed its second full utility patent application for an Antiviral Compositions and Methods Therefor (March 2012).
Amrita's Susan Finston was interviewed for BIOtecnNow as the 2011 Buzz of BIO Winner (Healing) at the 2011 BIO International Convention (March 20, 2012).
Amrita's Ananda Chakrabarty is a featured speaker at Biotechnologia Habana 2012: Medical Applications of Biotechnology, Havana International Conference Center, Havana, Cuba (5 – 8 March 2012), and the program may be downloaded here. Media coverage of his remarks is available here.
Amrita's Ananda Chakrabarty is a special guest at the Honorable William C. Conner Inn of Court program entitled: "Patentable Subject Matter: A Conversation with Dr. Ananda Chakrabarty," held in New York (16 February 2012).
Amrita's Ananda Chakrabarty's latest article: "Bacterial Proteins: A New Class of Cancer Therapeutics," has been published in the prestigious Journal of Commercial Biotechnology (JCB), described as the Harvard Business Review for biotechology companies. The abstract is available here.
An updated non-confidential overview of Amrita Therapeutics' market-disturbing research program is available for download here.
BIOWorld Today (10 Nov 2011) highlights key issues relating to biotechnology development in China and India featuring views of Amrita CEO/MD Susan Finston.
Amrita's Susan Finston shares latest trends and developments in India's burgeoning biotechnology sector as part of the BIOWorld webinar: "International Biotechnology: Emerging Trends from China and India, 27 October 2011. Her presentation is available to view as slides or in handout form. More information on how to view the BIOWorld webinar is available here.
Amrita's Ananda Chakrabarty is a guest speaker at the Eighth Annual Meeting of the Science and Technology in Society (STS) Forum on "Science and Technology for the Future of Humankind," held 2 – 4 October 2011 in Kyoto, Japan.
Amrita Therapeutics files its first full utility patent with the Indian Patent Office (IPO) and internationally under the Patent Cooperation Treaty (PCT) for an anti-cancer agent, 30 September 2011.
Recent interview with Amrita Therapeutics' Co-Founder and Science Advisor Ananda M. Chakrabarty, PhD., on recent research progress, is available here.
Amrita's Ananda Chakrabarty leads panel discussion on the role of IP protection in fueling life sciences innovation at the Confederation of Indian Industry (CII) Life Sciences Conclave 2011: Enabling Growth through Collaborative R&D and Technology Transfer, on 30 August in New Delhi, India. The detailed CII Life Sciences Conclave 2011 program is available here.
Amrita's Susan Finston participates as a guest lecturer for: "Genetic Resources & Traditional Knowledge: An Intellectual Property (IP) Primer," at the WIPO/US Summer School, hosted by the U.S. Patent and Trademark Office (PTO) on 10 August in Alexandria, VA. Her presentation is available for download here.
Amrita Therupeutics Voted as Buzz of BIO for the 2011 Annual International Convention!
As the Buzz of BIO Winner (Healthcare), Amrita Therapeutics presented at the BIO Business Forum, Wednesday, 29 June 2011, at the Walter E.Washington Convention Center, at the BIO 2011 Convention. Watch Amrita Therapeutics' BIO Business Forum:
Amrita's Ananda Chakrabarty is a featured speaker at the Biotechnology Industry Organization – U.S. Patent & Trademark Office (PTO) Event: Celebrating 30 Years of Biotechnology Innovation:From Diamond v. Chakrabarty To Today, held in conjunction with the BIO 2011 Annual Convention on 30 June 2011,9:00 –11:00 a.m. at the Walter E.Washington Convention Center, Room 102AB.
Amrita Therapeutics Co-Founders Ananda M. Chakrabarty, PhD and Susan K. Finston, JD/MPP lead dicussion of innovative programs for bio-pharmaceutical development in India: "Closing the Funding Gap in India for Commercialization of Biotechnology: Moving From Possibility to Opportunity," as part of an all-star panel at BIO 2011 at the Convention Center in Washington DC, 3:45 PM to 5:00 PM on Tuesday, 28 June 2011 in Room 152 B.
Watch Amrita Therapeutics Co-Founder and Science Advisor Ananda M. Chakrabarty, PhD. describe his creative process of innovative drug discovery and development for the India Biotechnology Delegation on 27 June 2011:
Amrita Therapeutics congratulates CDG Therapeutics, Ananda Chakrabarty's biotech start-up, co-founded with Dr. Tapas Das Gupta, on successful completion of its first-in-man Phase I Clinical Trial of lead candidate P28, presented at the ASCO 2011 Annual Meeting, 6 June 2011.
Amrita Therapeutics appoints Saionton Basu, Penningtons Solicitors, LLC, as international legal counsel to advise the company on cross-border legal issues including joint-ventures, fund raisings, and technology collaborations.
Amrita Therapeutics Senior Science Advisor and Co-Founder Ananda M. Chakrabarty, PhD, is Keynote Speaker at The John Marshall Law School's 2nd Annual Review of Intellectual Property Law Symposium, "Biotechnology and Health Issues in IP Law," in Chicago, Illinois on April 15, 2011. The full agenda and slate of speakers is available here.
Amrita Therapeutics files its latest Provisional Patent Application on methods of isolating protein drugs from microorganisms effective against HIV/AIDS.
In "Looking Back to Move Forward," (Biotech News, April 2011), Ananda Chakrabarty celebrates 25 years of shared biotechnology history on the occasion of the Department of Biotechnology (DBT) Silver Jubilee, including reflections on the past, present and future of biotechnology in India, and expressing appreciation for ongoing grant support for Amrita Therapeutics' path-breaking work on development of peptdie drugs with effectiveness against cancer and HIV.
Amrita Therapeutics CEO and Managing Director Susan K. Finston is a speaker at the University of Baltimore Law School, the IP Law Journal (IPLJ) and IP Law Society (IPLS) Spring Symposium on "The Incentive to Invent: Intellectual Property Protection and the U.S. Pharmaceutical and Biotechnology Industries," where she will address special issues affecting innovative biotech discovery companies in developing countries. The event will take place in Baltimore, MD on March 16, 2011.
Amrita Therapeutics Senior Science Advisor and Co-Founder Dr. Ananda M. Chakrabarty, and CEO/MD Susan K. Finston are provide insights on U.S. Patent Legislation following its passage by the U.S. Senate, available online here.
Amrita Therapeutics Senior Science Advisor and Co-Founder Dr. Ananda M. Chakrabarty addresses the topic,"Looking at the Crystal Ball: Where will our Next Generation Drugs Come From?", duing the National Science Day Celebration organized by the Agharkar Research Institute in Pune on February 22, 2011. Coverage of his remarks is available here.
Amrita Therapeutics Senior Science Advisor and Co-Founder Dr. Ananda M. Chakrabarty delivers an address entitled: "Anticancer potential of the newly chenically synthesized peptides," as chief guest at the International Symposium on 'Omics Approach to Microbes," organized by the National Environmental Engineering Research Institute (NEERI), Nagpur on February 17, 2011.
Amrita Therapeutics CEO and Managing Director Susan K. Finston serves as guest faculty for the National Institute of Health (NIH) Foundation for Advanced Education in the Sciences (FAES) Spring 2011 Course, "Biotechnology Business Leadership & Management Strategies,' Rockville, MD on February 15, 2011.
Amrita Therapeutics files its Provisional Patent Application with the Indian Patent Office for methods of isolation of promiscuous protein drugs from microorganisms.
Amrita Therapeutics files its Provisional Patent Application with the Indian Patent Office for a novel biomedical device for in situ cancer therapy.
Amrita Therapeutics CEO and Managing Director Susan K. Finston is serving as a Challenge Community Leader for the 2nd Phase GE ecomagination Challenge: Powering Your Home,
open for submission of new ideas to generate, utilize and conserve power in the home between 18 January and 1 March 2011.
Amrita Therapeutics Head of Research Dr. Prabhakar Salunkhe participates in the Gujarat Bio-Invest Seminar (December 22, 2010), organized by the Government of Gujarat together with the Association of Biotechnology Led Enterprises (ABLE) and the Gujarat State Biotechnology Mission (GBSTM) as a break-out event of Vibrant Gujarat 2011.
A narrative version of the Amrita presentation is available here.
Amrita Therapeutics Head of Research Dr. Prabhakar Salunkhe delivers an invited talk in the National Conference on Biotechnology for All (2010), organized by the North Maharashtra University Jalgoan (December 29 - 30, 2010).
Amrita Therapeutics Senior Science Advisor and Co-Founder Ananda M. Chakrabarty, PhD., is an eminent invited speaker at the B. V. Patel PERD Centre's 6th International Symposia organized in Ahmedabad, Gujarat (26 – 28 November 2010). Dr. Charkabarty's presentation, "Bacterial Proteins as Potential Multi-Disease-Targeting Drugs," focused on new concepts and latest developments in novel peptide-drug and related delivery systems.
More information on the PERD Centre's 6th International Symposium is available here.
Amrita Therapeutics Limited (ATL) welcomes Mr. Mohan Harshey, Director, Private Equity at Tata Capital Ltd., as a Independent Director of the Company.
Amrita Therapeutics initiates collaborative research with the Center for DNA Fingerprinting and Diagnostics (CDFD), an apex research institute and an autonomous organization funded by the Department of Biotechnology (DBT).
Amrita Therapeutics files its first Provisional Patent Application with the Indian Patent Office for a broad spectrum cancer agent of microbial origin.
Amrita Therapeutics' Senior Science Advisor and Co-Founder, Dr. Ananda M. Chakrabarty, and CEO and Co-Founder Susan K. Finston are featured in Setpember 2010 Express Pharma and Express Biotech online publications. The Express Pharma OpEd highlights Amrita's as part of the paradigm shift for Indian life sciences innovation, available here. The second article in the current issue of Express Biotech outlines the company's proprietary science platform and recent research developments, available here.
On 21 - 22 September 2010, the University of Illinois honored Dr. Ananda M. Chakrabarty with a seminar honoring the 30th Anniversary Celebration of the landmark U.S. Supreme Court decision Diamond vs. Chakrabarty (1980), which for the first time permitted patent rights for genetically engineered organisms. More information on panel topics, eminent guests, expert speakers, and other details of the University of Illinois two-day program can be found here.
Amrita Therapeutics Senior Science Advisor and Co-Founder, Dr. Ananda M. Chakrabarty, chairs a special session on Intellectual Property Rights and Technology Transfer at the 2010 Indo/U.S. Life Sciences Conclave, in New Delhi, on 18 - 19 August. The 2010 Life Sciences Conclave provides a forum for leading scientists and senior company officials to realize India's potential as a global centre for bio-pharmaceutical innovation, and to promote collaboration for commercialization of science and creation of social and economic value through development new products and services.
For more information or to register for the event, contact Ravikiran Veligeti, Executive Officer, Confederation of Indian Industry (CII).
Amrita Therapeutics initiates collaborative research with the National Institute of Immunology, an autonomous research institute supported by the Department of Biotechnology (DBT) in New Delhi, India. The NII is a globally recognized center of excellence for advanced research relating to mechanisms to defend the human body from pathgens including cancers and other public health threats.
The Biotechnology Industry Organization (BIO), the pre-eminent global trade association for the innovative life sciences, recognizes the 30th Anniversary of Diamond vs. Chakrabarty, the seminal U.S. Supreme Court decision that established the core principle that genetically engineered organisms may be eligible for patent protection. The Statement released by BIO President and CEO Jim Greenwood can be found here.
Amrita Therapeutics welcomes Mr. Raghavendran Iyer, Bachelor of Commerce (B.com.), L. J. Commerce College, Ahmedabad, as Administration and Finance Manager, based in our offices at PERD Centre, Ahmedabad.
Amrita Therapeutics CEO, Mrs. Susan K. Finston provides a plenary presentation on development of innovative life sciences in the Middle East North Africa (MENA) markets for creation of social and economic value, at the MENA Women in Science and Technology Workshop, in Abu Dhabi, UAE, 3 May 2010, organized by the National Science Foundation (NSF), together with the Univiersity of Michigan, Dearborn, and the U.S. Department of States, and with sponsorship by the Dow Chemical Company.
Amrita Therapeutics has been awarded a two-year grant by the Department of Biotechnology (DBT) under the Biotechnology Industry Promotion Program (BIPP) to support collaborative research to identify and develop promiscuous anti-cancer compounds from microorganisms.
More information on the BIPP and current programs under development, including Amrita Therapeutics, is available here.
Amrita Therapeutics has initiated a new program of early research to identify additional promising, innovative molecules at the B.V. Patel Pharmaceutical Education & Research Development (PERD) Centre, the first multidisciplinary, advanced pharmaceutical research institute in Ahmedabad, India. For more information on the PERD Centre, click here.
Amrita Therapeutics welcomes Mr. Pravin Kumar Jha, M.S. Degree (Pharmacy) with specialization in Pharmaceutical Biotechnology from the National Institute of Pharmaceutical Education & Research (NIPER) Ahmedabad, and Bachelor of Pharmacy from Poona College of Pharmacy, at Bharati Vidyapeeth University Pune, and Ms. Payal Bhatnagar, M.Sc. Biotechnology Degree from G.H. Raisoni Institute of Interdisciplinary Science, Nagpur University to support Amrita's early research program.
Amrita Therapeutics Senior Science Advisor, Dr. Ananda M. Chakrabarty, CEO Susan K. Finston, and the Amrita Therapeutics senior management team participated in Focused Group Discussions convened by the the Micro, Small and Medium Enterprises Foundation (MSME Foundation) under the auspices of the Government of India's Department of Science and Technology program: Promoting Innovative Clusters (PIC), to identify action steps towards deveopment of innovative life sciences in the state of Gujarat, India. Susan K. Finston also provided copies of the latest BayhDole25 Biotechnology Toolkit addressing similar issues, namely the core elements of an enabling envirionment for the innovative life sciences. The Focused Group Discussion provided a number of practical action steps that the MSME Foundation will take up in coordination with DST in the coming weeks and months to support SME deveopment in four broad categories: pharmaceutical (new formulations and drug delivery systems), medical devices, biotechnology start-ups (like Amrita Therapeutics) and traditional medicines.
For background information on the MSME Foundation, visit: http://www.msmefoundation.org/
To download the BayhDole25 Biotechnology Toolkit, visit: www.bayhdole25.org
Amrita Therapeutics Senior Science Advisor, Dr. Ananda M. Chakrabarty, reviews his pioneering role in establishing patentiability of genetically engineered (GE) organisms as lead panelist at Tech Council of Maryland event: "IP Issues in Biotech following the U.S. Supreme Court Case Diamond v. Chakrabarty," held on 2 September 2009 in Rockville, Maryland. For more details, click here.
In Memorium: Amrita Therapeutics mourns the loss of Mr. Vishnu Varshney, GVFL Founder and CEO Emeritus, who passed away after a brief illness on July 29, 2009.
Amrita Therapeutics Senior Science Advisor and Co-Founder, Dr. Ananda M. Chakrabarty was the featured speaker that George Washington University Law School's Second Annual A. Sidney Katz Intellectual Property Law Speaker Event, held on 16 April at the Law School in Washington DC. In addition to providing insights into the original development of the first patented genetically engineered (GE) organisim, Dr. Chakrabarty discussed the science platform underlying Amrita Therapeutics' pioneering research in the area of multiple disease targetting (MDT) drugs. To learn more, click here.
Amrita Therapeutics CEO Susan K. Finston was a featured speaker at: "Equity and Commercial Rights for Genetic Resources," cosponsored by the DC Bar Associations and the Environmental Law Institute, held on 29 April 2009, in Washington DC, and considered key issues relating to sustainable commercial uses and equitable sharing of benefits from genetic resources. Finston's presentation focused on key outstanding issues relating to the ongoing negotiation of operational text for the International Regime (IR) for Access and Benefit Sharing in the Convention on Biological Diversity (CBD) likely to be presented to Ministers for adoption in October 2010.
For full details on the DC Bar/ELI event, click here.
To download Susan Finston's presentation (handout), click here.
Amrita Therapeutics outlines immediate R&D goals and benchmarks for development of Multiple Disease Targeting (MDT) Drugs for prevention and treatment of cancer, and HIV, among other public health threats. To learn more, click here.
Amrita Therapeutics participates in Vibrant Gujarat (12 - 13 January 2009) at Science City, Ahmedabad. (Image at left from the GVFL booth featuring Amrita Therapeutics at Vibrant Gujarat.)
Amrita Therapeutics welcomes Dr. Prabhakar Salunkhe, Ph. D. in Biochemistry from Medical Research Institute, Hannover, Germany; MS (Biochemistry), B.Sc (Chemistry), as Head of Research, based in Ahmedabad, Gujarat at PERD Centre.
Amrita Therapeutics welcomes Mr. Ruchir Shah, M.B.A., Pharmaceutical Business, from the University of the Sciences Philadelphia, B.S., Pharmacy, as Operations Manager for Amrita Therapeutics, based in Ahmedabad, Gujarat at PERD Centre. To learn more about his background and training, click here.
Amrita Therapeutics has initiated a research collaboration agreement with the B.V. Patel Pharmaceutical Education & Research Development (PERD) Centre, the first multidisciplinary, advanced pharmaceutical research institute in Ahmedabad, India. For more information on the PERD Centre, click here.
GVFL, India’s leading venture capital company, has invested in Amrita Therapeutics. For more details, click here.